Jenny Wilkerson

Jenny Wilkerson, Ph.D.

Research Assistant Professor

Department: Pharmacodynamics
Business Phone: (352) 294-8908
Business Email: jenny.wilkerson@cop.ufl.edu

About Jenny Wilkerson

Jenny Wilkerson, Ph.D., joined the University of Florida College of Pharmacy in November 2017 as a research assistant professor in the department of pharmacodynamics. Wilkerson received her Bachelor of Science degree in cellular/ molecular biology, with a minor in chemistry, from Northwest Missouri State University, and her Ph.D. in biomedical sciences from the University of New Mexico School of Medicine’s department of neurosciences. Upon completion of her doctoral studies, Wilkerson completed a postdoctoral fellowship at Virginia Commonwealth University in the department of pharmacology and toxicology, where she was the recipient for the competitive Ruth L. Kirschstein F32 Individual National Research Service Award. Her research interests broadly encompass the involvement of the immune system in preclinical models of pathological pain and neurodegeneration, with an emphasis on endogenous cannabinoid (endocannabinoid) system modulation. Additionally, an area of keen interest of Wilkerson’s is the examination of the adjunct administration of experimental preclinical compounds to produce enhanced analgesic opioid effects, with diminished drug abuse liability.

Publications

2021
Characterization of a mouse neuropathic pain model caused by the highly active antiviral therapy (HAART) Stavudine.
Pharmacological reports : PR. 73(5):1457-1464 [DOI] 10.1007/s43440-021-00262-y. [PMID] 33860918.
2021
Peripherally administered cannabinoid receptor 2 (CB2R) agonists lose anti-allodynic effects in TRPV1 knockout mice, while intrathecal administration leads to anti-allodynia and reduced GFAP, CCL2 and TRPV1 expression in the dorsal spinal cord and DRG
Brain Research. 1774 [DOI] 10.1016/j.brainres.2021.147721. [PMID] 34774500.
2021
Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy for μ-Opioid Receptor and Opioid-Like Behavioral Effects in Rats.
The Journal of pharmacology and experimental therapeutics. 376(3):410-427 [DOI] 10.1124/jpet.120.000189. [PMID] 33384303.
2021
Sex differences and the endocannabinoid system in pain.
Pharmacology, biochemistry, and behavior. 202 [DOI] 10.1016/j.pbb.2021.173107. [PMID] 33444598.
2021
Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline?
Pharmacology, biochemistry, and behavior. 206 [DOI] 10.1016/j.pbb.2021.173192. [PMID] 33932409.
2020
Advances in the In vitro and In vivo pharmacology of Alpha4beta2 nicotinic receptor positive allosteric modulators.
Neuropharmacology. 168 [DOI] 10.1016/j.neuropharm.2020.108008. [PMID] 32113032.
2020
Alterations in mouse spinal cord and sciatic nerve microRNAs after the chronic constriction injury (CCI) model of neuropathic pain.
Neuroscience letters. 731 [DOI] 10.1016/j.neulet.2020.135029. [PMID] 32380144.
2020
Axially Chiral Cannabinols: A New Platform for Cannabinoid-Inspired Drug Discovery.
ChemMedChem. 15(9):728-732 [DOI] 10.1002/cmdc.202000025. [PMID] 32061146.
2020
More than Smoke and Patches: The Quest for Pharmacotherapies to Treat Tobacco Use Disorder.
Pharmacological reviews. 72(2):527-557 [DOI] 10.1124/pr.119.018028. [PMID] 32205338.
2020
Nicotinic Acetylcholine Receptor Accessory Subunits Determine the Activity Profile of Epibatidine Derivatives.
Molecular pharmacology. 98(4):328-342 [DOI] 10.1124/molpharm.120.000037. [PMID] 32690626.
2020
Peripheral versus central mechanisms of the cannabinoid type 2 receptor agonist AM1710 in a mouse model of neuropathic pain.
Brain and behavior. 10(12) [DOI] 10.1002/brb3.1850. [PMID] 32977358.
2020
Unexpected loss of sensitivity to the nicotinic acetylcholine receptor antagonist activity of mecamylamine and dihydro-β-erythroidine in nicotine-tolerant mice.
Brain and behavior. 10(4) [DOI] 10.1002/brb3.1581. [PMID] 32092237.
2019
Pharmacological characterization of mitragynine, the primary constituent in Kratom, as a potential medication for opioid use disorder
Journal of pharmacological and toxicological methods (Online). [DOI] 10.1016/j.vascn.2019.05.012. [PMID] 31963089.
2019
The effects of mitragynine and morphine on schedule-controlled responding and antinociception in rats.
Psychopharmacology. 236(9):2725-2734 [DOI] 10.1007/s00213-019-05247-7. [PMID] 31098655.
2019
The Effects of Morphine, Baclofen, and Buspirone Alone and in Combination on Schedule-Controlled Responding and Hot Plate Antinociception in Rats.
The Journal of pharmacology and experimental therapeutics. 370(3):380-389 [DOI] 10.1124/jpet.118.255844. [PMID] 31235534.
2019
Tolerance and dependence to Δ9-tetrahydrocannabinol in rhesus monkeys: Activity assessments.
PloS one. 14(3) [DOI] 10.1371/journal.pone.0209947. [PMID] 30861005.
2017
Investigation of Diacylglycerol Lipase Alpha Inhibition in the Mouse Lipopolysaccharide Inflammatory Pain Model.
The Journal of pharmacology and experimental therapeutics. 363(3):394-401 [DOI] 10.1124/jpet.117.243808. [PMID] 28970359.
2017
The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice.
Neuropharmacology. 114:156-167 [DOI] 10.1016/j.neuropharm.2016.11.015. [PMID] 27890602.
2016
Diacylglycerol lipase β inhibition reverses nociceptive behaviour in mouse models of inflammatory and neuropathic pain.
British journal of pharmacology. 173(10):1678-92 [DOI] 10.1111/bph.13469. [PMID] 26915789.
2016
Palmitoylethanolamide Reverses Paclitaxel-Induced Allodynia in Mice.
The Journal of pharmacology and experimental therapeutics. 359(2):310-318 [PMID] 27608657.
View on: PubMed
2016
The novel, orally available and peripherally restricted selective cannabinoid CB2 receptor agonist LEI-101 prevents cisplatin-induced nephrotoxicity.
British journal of pharmacology. 173(3):446-58 [DOI] 10.1111/bph.13338. [PMID] 26398481.
2016
The Selective Monoacylglycerol Lipase Inhibitor MJN110 Produces Opioid-Sparing Effects in a Mouse Neuropathic Pain Model.
The Journal of pharmacology and experimental therapeutics. 357(1):145-56 [DOI] 10.1124/jpet.115.229971. [PMID] 26791602.
2016
The α7 nicotinic receptor dual allosteric agonist and positive allosteric modulator GAT107 reverses nociception in mouse models of inflammatory and neuropathic pain.
British journal of pharmacology. 173(16):2506-20 [DOI] 10.1111/bph.13528. [PMID] 27243753.
2015
Selective monoacylglycerol lipase inhibitors: antinociceptive versus cannabimimetic effects in mice.
The Journal of pharmacology and experimental therapeutics. 353(2):424-32 [DOI] 10.1124/jpet.114.222315. [PMID] 25762694.
2014
Improvement of spinal non-viral IL-10 gene delivery by D-mannose as a transgene adjuvant to control chronic neuropathic pain.
Journal of neuroinflammation. 11 [DOI] 10.1186/1742-2094-11-92. [PMID] 24884664.
2013
Mesoporous silica-supported lipid bilayers (protocells) for DNA cargo delivery to the spinal cord.
Journal of controlled release : official journal of the Controlled Release Society. 168(2):209-24 [DOI] 10.1016/j.jconrel.2013.03.009. [PMID] 23517784.
2012
Immunofluorescent spectral analysis reveals the intrathecal cannabinoid agonist, AM1241, produces spinal anti-inflammatory cytokine responses in neuropathic rats exhibiting relief from allodynia.
Brain and behavior. 2(2):155-77 [DOI] 10.1002/brb3.44. [PMID] 22574283.
2012
Intrathecal cannabilactone CB(2)R agonist, AM1710, controls pathological pain and restores basal cytokine levels.
Pain. 153(5):1091-1106 [DOI] 10.1016/j.pain.2012.02.015. [PMID] 22425445.
2011
The Central Role of Glia in Pathological Pain and the Potential of Targeting the Cannabinoid 2 Receptor for Pain Relief.
ISRN anesthesiology. 2011(2011) [PMID] 22442754.
View on: PubMed

Grants

Jul 2019 – Dec 2020
Consortium for Medical Marijuana Clinical Outcomes Research
Role: Project Manager
Funding: STATE UNIVERSITY SYSTEM OF FLORIDA via FL LEGISLATURE
Jun 2019 ACTIVE
Opioid and cannabinoid interactions in pain and reward
Role: Co-Investigator
Funding: UF RESEARCH

Education

Ph.D.
2012 · University of New Mexico
B.S.
2004 · Northwest Missouri State University

Teaching Profile

Courses Taught
2019-2020
PHA5560 Pathphys-Pt Assess I
2020
PHA4911 Undergraduate Research in Pharmacodynamics
2021
PHA7979 Advanced Research

Contact Details

Phones:
Business:
(352) 294-8908
Emails: